Mind Medicine (MindMed) Inc (NEO:MMED)(OTCQB:MMEDF) CEO JR Rahn the leading drug development company for psychedelic-inspired medicines tells Proactive the group is evaluating an expanded US investor base through an up-listing on the Nasdaq Capital Market. What's more, Rahn says MindMed is committing $5 million over five years to establish and launch a program to train the next generation of psychiatrists and clinical investigators in the field of psychedelic assisted therapies and medicines.
MindMed Inc. looks to up-list to the Nasdaq amidst rise in popularity of psychedelic medicines
Quick facts: MindMed
Price: 1.64 USD
Market Cap: $534.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE